Tag Archives: MEQ

PR Newswire

Vela Diagnostics receives CE-IVD approval and Provisional Authorisation from the Health Sciences Authority in Singapore for automated COVID-19 detection test

Leave a comment

SINGAPORE, July 13, 2020 — Vela Diagnostics announced today that an automated version of its COVID-19 detection test, the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0, has received the CE mark for in vitro diagnostic use as well as Provisional Authorisation from the Health Sciences Authority in Singapore.

The ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 is a probe-based reverse transcription PCR Test that detects SARS-CoV-2 by targeting conserved regions of the SARS-CoV-2 genome, specifically the ORF1a and N genes. The automated test is optimized for a workflow consisting of the Sentosa™ SX101 instrument, in conjunction with the Sentosa™ SA201 instrument or the ABI 7500 Fast Dx. The automated workflow enables high throughput testing with significantly reduced hands-on time. Up to 48 tests, including controls, can be performed in a single run. “Receiving CE certification and Provisional Authorisation from the Health Sciences Authority in Singapore for our automated test facilitates efficient testing of SARS-CoV-2 in patients suspected of COVID-19 in Europe, Africa, Middle East and Asia, where there is an urgent need to identify individuals infected with SARS-CoV-2 for effective management of the global pandemic,” said Managing Director, Andreas Goertz.

In April this year, an earlier version of the test, the ViroKey™ SARS-CoV-2 RT-PCR Test, also received the CE mark and Provisional Authorisation from the Health Sciences Authority in Singapore.

About Vela Diagnostics

Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA’s test solutions utilize the automated Sentosa™ platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.

All Sentosa™ products listed above are by Vela Diagnostics. For more information, visit www.veladx.com.

Related Links :

http://www.veladx.com

PR Newswire

United Imaging Announces New Technology That Advances Molecular Imaging, Hints at a Series of New Announcements

Leave a comment

Company is sponsoring its second SNMMI Annual Meeting.

HOUSTON, July 11, 2020 — United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, continues to set a new standard in molecular imaging and redefine nuclear medicine. The company has begun unveiling new technology that showcases more of its all-digital platform and its significant commitment to U.S. market growth. United Imaging will host a virtual booth at the 2020 SNMMI Annual Meeting and will meet with customers in that environment and through its own virtual meeting technology.

“United Imaging is taking a unique look at this industry,” said Jeffrey M. Bundy, Ph.D., CEO, United Imaging Healthcare Solutions in the U.S. “We built a company that from the ground up is designed for modern solutions, to address needs American healthcare providers wanted addressed. In just one short year since the last SNMMI meeting, we’ve moved fast. I think when people chat with us this year, although there is no in-person conference to physically see and touch our booth, they’ll learn that we’ve done exactly what we set out to do.”

For SNMMI, United Imaging announced that HYPER Iterative functionality is FDA cleared for its uMI 550 digital positron emission tomography (PET) / computed tomography (CT) scanner. This solidifies the company’s commitment to address the needs of the American patient. HYPER Iterative can achieve high image contrast and quantification accuracy while giving users the flexibility to reduce scan times and improve patient comfort.

In addition, United Imaging was the first in the U.S. to launch a mobile digital PET/CT unit, which will dramatically improve patient access to state-of-the-art imaging tests, including digital technology that was only available previously in fixed locations, and predominantly in large institutions or academic settings. The uMI 550 mobile scanner will hit the road to perform clinical scans this summer.

“This first-ever mobile digital PET/CT unit dramatically changes the game and makes research-level technology accessible to more people,” said Cheri Gottke, vice president of United Imaging’s molecular imaging portfolio in the U.S. “United Imaging has been leading in terms of achieving access, making this valuable — now mobile — digital PET/CT technology available to providers and patients in urban, suburban, and rural regions alike.”

Artificial intelligence (AI) remains the focus of substantial investment by the company. United Imaging also has announced the introduction of uAI technologies into key radiology systems with HYPER Deep Learning Reconstruction* in the routine PET/CT workflow of its uMI 550 and uMI 780 digital PET/CT systems to enhance image quality.

United Imaging also announced that more than 3,500 clinical patients have been scanned on its uEXPLORER® total-body PET/CT system. The average patient clinical total-body scan time is 1-3 minutes.

United Imaging developed uEXPLORER in partnership with the EXPLORER Consortium led by Simon Cherry, Ph.D., and Ramsey Badawi, Ph.D., from the University of California, Davis. The two were recently honored for that achievement with a 2020 Innovator of the Year Award from their university. uEXPLORER also received a Gold Award and a Silver Award in the 2020 American Business Awards.

“The core uEXPLORER technology is actually embedded in every product in our MI portfolio,” said Gottke. “Also, the MI portfolio — and in fact all of our modalities — features what we call our ‘all-in’ approach, meaning that our systems ship with every feature already included, so customers can simply implement them as their needs change.”

Learn more about United Imaging’s presence at SNMMI here.

* Pending 510(k), not available for sale in the United States.

ABOUT UNITED IMAGING

At United Imaging, we develop and produce advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our U.S. R&D facility opened in 2013 in Houston and was further established as the U.S. headquarters in 2018 with our service team and commercial organization in place. With a cutting-edge digital portfolio and a mission of broader access to healthcare for all, we help drive industry progress and bold change.

To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC.

Related Links :

http://www.united-imaging.com

PR Newswire

Paige Applauded by Frost & Sullivan for its Leading AI-based Computational Pathology Offering that Enables Fast and Accurate Cancer Diagnoses

Leave a comment

Paige leveraged the world’s largest dataset in pathology to develop an unparalleled computation pathology offering

SANTA CLARA, California, July 8, 2020 — Based on its recent analysis of the North American AI-based digital pathology market, Frost & Sullivan recognizes Paige with the 2020 North American Enabling Technology Leadership Award for its disruptive product offering.

Paige
Paige

Paige has developed robust machine learning models for computational pathology for detecting cancer subtypes, thereby enhancing the diagnosis capability of pathologists worldwide. Paige’s AI-based technology was developed and tested on over 100,000 de-identified, digitized slide images from more than 16,000 cancer patients. The deep learning algorithms detected prostate cancer, skin cancer, and breast cancer with near-perfect accuracy.   

“Paige’s AI algorithms validated against the world’s largest dataset in pathology makes it the most trustworthy best in class pathology diagnosis solution,” said Debarati Sengupta, Industry Analyst, Frost & Sullivan. “Paige’s technology eliminates the need to curate datasets, which is time-consuming and expensive. Paige’s AI based pathology offering enables pathologists to make a fast and accurate diagnosis of even the most complex and difficult to interpret slides.”

The Paige offering consists of general and organ-specific products that provide rapid diagnostic stratification, cancer detection, tumor segmentation, and prediction of treatment response, and overall survival. Its algorithms form a portfolio of AI-based digital diagnostics and biomarkers to help pathologists provide diagnoses. For security purposes, all datasets used to build the products were de-identified, and any protected health information or label text was removed.

Notably, Paige’s computational pathology offering received the Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2019, making it the first such device for cancer diagnosis. Furthermore, it began commercializing in 2019 following its CE mark approval for Paige Prostate, which is a first-to-market prostate cancer detection solution, and a digital pathology viewer for the primary diagnosis of any digital slide. Paige’s AI-based solutions are vendor agnostic, which helps it serve a wider pool of customers.

In 2020, it formed a strategic partnership with Invicro LLC, a Konica Minolta company to provide its AI-based integrated pathology solutions to support Invicro’s drug discovery and development initiatives. “Paige continues to expand its footprint not just in commercial laboratories, but also in biopharmaceutical companies, positioning itself as a pioneer in AI-based digital pathology market” noted Sengupta.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of new products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Kristen Moore
P: 210.247.3823
E: kristen.moore@frost.com

About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center.  The Company builds computational pathology products designed so patients and their care teams can make faster, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity.  Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Our products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first and only company to receive FDA breakthrough designation for computational pathology products.

For additional information, please visit:  https://www.Paige.ai  Twitter and LinkedIn

Media Contact:
NRPR Group
Nicole Rodrigues
(650) 815-5069
nicole@nrprgroup.com

Related Links :

http://www.frost.com

PR Newswire

Xovis Multiplies Your Options in One Fell Swoop

Leave a comment

Two new AI features for in-store analytics made possible by Xovis 3D sensors

ZOLLIKOFEN, Switzerland, July 2, 2020 — When their ordinary "all-in-a-day’s-work" became extraordinary, Xovis ramped up their R&D to solve unforeseen challenges. Today, the company proudly presents two new AI features for their 3D people counting sensors: Face Mask Detection and View Direction. While View Direction had been hinted at in January this year, Face Mask Detection has sprung up out of the current situation with COVID-19. Xovis hopes that this will help their customers stay on top of public health regulations. The company’s innovative and GDPR compliant technology becomes the only kind to detect face masks directly on 3D sensors.

The Xovis Face Mask Detection
The Xovis Face Mask Detection

 

The Xovis View Direction
The Xovis View Direction

As Xovis Head of Retail Anne Wyder explains, "COVID-19 has made face masks compulsory in many public places; we have responded by developing a new AI feature for our sensors to recognize whether or not face masks are in fact being worn. In a bid to help businesses adhere to public health regulations, this new software plugin for Face Mask Detection will be free of charge until the end of the year for our integrator partners working with the Xovis Cloud Account." 

Despite COVID-19, and at the same time because of the global crisis that has ensued, Xovis is actively providing technological solutions for both occupancy and physical distancing management. As Xovis CPO Christian Studer puts it: "We have been busy – we’ve not only finished development of the much-anticipated View Direction plugin for in-store analytics, but in an agile response to changing market demands also stepped up to the plate and created something extra in our firmware for our customers. Both Face Mask Detection and View Direction features provide deeper insight into customer behavior – the analysis of which has become more important than ever before."

As the undisputed innovator of people flow technology based on 3D stereovision sensors, Xovis is committed to bringing the best products and services to customers and partners alike. Because people count.

See how Xovis detects Face Masks

Read how Xovis View Direction works

Click here for more about Xovis Physical Distancing Solutions

Photo – https://techent.tv/wp-content/uploads/2020/07/xovis-multiplies-your-options-in-one-fell-swoop-3.jpg  
Photo – https://techent.tv/wp-content/uploads/2020/07/xovis-multiplies-your-options-in-one-fell-swoop.jpg  
Logo – https://techent.tv/wp-content/uploads/2020/07/xovis-multiplies-your-options-in-one-fell-swoop-2.jpg

Company Contact
Xovis
Industriestrasse 1
3052 Zollikofen
Switzerland
+41-32-342-04-70
info@xovis.com

Media Contact
Christian Studer, CPO
+41-32-508-35-41
christian.studer@xovis.com

Related Links :

https://www.xovis.com/

PR Newswire

icometrix launches its icompanion platform for people with multiple sclerosis

Leave a comment

LEUVEN, Belgium and CHICAGO, June 2, 2020 /PRNewswire/ — icometrix, the world leader to extract clinically meaningful data from brain scans, is proud to have launched the icompanion platform and phone application for people with multiple sclerosis on World MS Day!  icompanion is a medical device and is currently available in English, French, German, and Dutch.

To support people with multiple sclerosis, icompanion provides an easy and secure app to track symptoms, treatments, and physician visits. Users can also obtain educational information on the meaning and quality of their brain scans by uploading their MRI scans onto the platform. With this, icompanion provides a solution to log events that occur between neurologist visits, by means of day-to-day symptom-tracking and standardized questionnaires (patient-reported outcomes).

“As a neurologist, you see a patient only a couple of times a year and we know that a lot of valuable information is lost in-between,” says Dr. Helmut Butzkeuven, neurologist at the Monash University in Melbourne, and director of MSBase, the largest global multiple sclerosis registry. “To make informed clinical and treatment decisions, it is important to have a complete picture of how a patient is doing,” Dr. Butzkeuven continues. “Medical devices such as icompanion can greatly help in democratizing care, since today, patient care depends on where you live and who cares for you,” Dr. Butzkeuven concludes.

“icompanion helps me keep track of my symptoms. Even if they seem insignificant, they are crucial in helping me communicate with my physician and prepare my visits. I think it’s great that by using icompanion, my data can also support researchers in their fight against multiple sclerosis. To win this battle we need everyone’s help, and together we are stronger,” shares Roberto Paolella, living with MS for 15 years.

“Offering care based on data and objective measures is crucial to move towards more personalized and precise medicine for people with neurological disorders,” says Wim Van Hecke, CEO of icometrix. “That is why we founded icometrix and developed the CE-labeled and FDA-cleared icobrain MR and CT brain measures, which are becoming standard of care. Through icompanion, the gap between doctor visits is bridged with clinically meaningful and validated data. The seamless availability of the icompanion data to the health care provider is very important in this context,” Wim Van Hecke states.

About icometrix 
icometrix is the world leader in software solutions to obtain clinically meaningful data from brain MR and CT scans for patients with neurological conditions such as multiple sclerosis, brain trauma, epilepsy, dementia, Alzheimer’s, Parkinson’s, etc. The fully automated icobrain software from icometrix is FDA cleared and CE labeled and leverages artificial intelligence to quantify disease-specific brain structures. Today, icometrix is internationally active in over 100 clinical practices. Alongside this, icometrix works with healthcare providers and pharmaceutical companies on the evaluation of drug trials for neurological diseases.

Please visit icompanion.ms for further information.

Contact
Wim Van Hecke, CEO
wim.vanhecke@icometrix.com
+32 484 92 73 00

Press Kit 
https://tinyurl.com/ybm7tjzm

Logo – https://techent.tv/wp-content/uploads/2020/06/icometrix-launches-its-icompanion-platform-for-people-with-multiple-sclerosis.jpg

PR Newswire

ActLight Signs an Agreement on Single Photon Sensitivity Technology With Leading Sensors Company

Leave a comment

LAUSANNE, Switzerland, May 27, 2020 /PRNewswire/ — ActLight, the Swiss technology firm known for its best in class signal-to-noise ratio photodiodes, announced today that it has signed a service agreement based on its Single Photon Sensitivity technology with a leading company in the sensors market.

Single Photon Sensitivity technology
Single Photon Sensitivity technology

“Even though the terms of the agreement cannot be disclosed, we are very pleased that our innovative Single Photon Sensitivity technology attracted a leading player in the sensors field,” said Maxim Gureev, Chief Technology Officer at ActLight. “The adoption of Single Photon Avalanche Diode (SPAD) array in 3D sensing chips is growing fast. The precision of 3D sensing in applications such as smartphones, cars and smart robotics will benefit from this collaboration with our customer and our talented team of engineers is already intensively working to make it happen.”

About ActLight SA

ActLight SA, the start-up company founded in 2011 and based in Switzerland, focuses on the field of CMOS photonics by developing a new type of photodetector, the Dynamic PhotoDiode (DPD). Being a fabless company, ActLight specializes in the Intellectual Property (IP) of this area and operates primarily in the IP licensing business model.

The patented CMOS-based photonics technology allows the substantial improvement of the efficiency and accuracy of various light sensing applications, such as Time Of Flight (TOF) based range meters, vital signs monitoring, 3D/2D cameras and much more. ActLight operates in the Internet of Things (IoT) market, with a focus on mobile and wearable devices, healthcare/medtech, autonomous driving, drones and robotics.

More info about ActLight available at http://www.act-light.com

Contact: 
info@act-light.com

Photo – https://techent.tv/wp-content/uploads/2020/05/actlight-signs-an-agreement-on-single-photon-sensitivity-technology-with-leading-sensors-company.jpg
Logo – https://techent.tv/wp-content/uploads/2020/05/actlight-signs-an-agreement-on-single-photon-sensitivity-technology-with-leading-sensors-company-1.jpg

PR Newswire

VeChain and I-Dante Partnered to Create Blockchain Enabled Medical Data Management Platform for Healthcare Provider in Cyprus

Leave a comment

SHANGHAI, May 18, 2020 /PRNewswire/ — With more than 4.6 million infections, 300 thousand deaths and counting caused by COVID-19, national governments, healthcare systems regardless of region and continent have been scrambling to respond to it, and the pandemic has highlighted the increasing demand for digital technologies to replace our old way of communication. VeChain is at the frontier of this digital transformation, solving the problems of the management of healthcare data by utilizing solutions powered by blockchain technology.

With the aim of enabling digital transformation in the healthcare sector, VeChain, together with I-Dante co-developed a blockchain-enabled medical data management platform named The E-NewHealthLife. Mediterranean Hospital of Cyprus, a hospital under the General Healthcare System of the Republic of Cyprus (GHS) is the first hospital to adopt this application.

Healthcare System Advancement
 There have been efforts to modernize the technological infrastructure in the healthcare sector, but the problems include the administrative and technical difficulties of pooling data from different digital systems, the increasing cost, and the balance of health imperatives and privacy concerns, have greatly hampered the efforts. This dilemma has led to an urgent need for a low-cost yet highly-efficient digital solution.

With proven advantages in terms of secured data storage and efficient information sharing between multiple parties, blockchain technology has emerged as the best option in hand.

Blockchainized Actions In Response To The Challenges
There is a strong and urgent demand to deliver better and more efficient healthcare solutions that can achieve excellent patient-centric healthcare provision, secured data sharing, while complying with regulations on the use and sharing of patient data, which is solved in this case by the introduction of the E-NewHealthLife Web App in the Emergency Department of the hospital as the first phase of this project.

Powered by VeChain ToolChainTM, the Digital Healthcare Passport is an encrypted NFC Card that can be assigned to any patient of the hospital. The NFC Cards will allow the patients to identify themselves automatically at the Emergency Room registration desk, check their queue on mobile phone, manage their own medical records safely with the E-NewHealthLife Web App.

The blockchain powered application can serve both the hospitals internally and also end users. As The E-NewHealthLife fully complies with the GDPR (EU’s General Data Protection Regulation), the App enables the owner to have complete control over their profile and medical records. Data can only be shared to 3rd parties with the permission of the owner.

Bridging Trust In The Healthcare Sector
 Blockchain is being posited as the next frontier in healthcare that will help solve the industry’s interoperability challenges. According to a report by BIS Research, the global healthcare market spending and investment on blockchain-based technologies is expected to hit $5.61 billion by 2025. The adoption of blockchain technology could save the healthcare industry up to $100–$150 billion per year by 2025.

Based on concrete cases of multi party collaboration in various industries, VeChain has been accumulating experience in bridging trust and bringing in transparency into business while being compliant with local authorities and regulators. Given the huge potential of blockchain technology in the medical and healthcare sector, VeChain will continue to develop solutions for all stakeholders and pursue more opportunities in the near future.

About Mediterranean Hospital of Cyprus

The Mediterranean Hospital of Cyprus is a modern private health care institution, one of the largest in Cyprus, with a mission to provide to all the citizens and the visitors of the country safe and high quality medical services 24/7. The founder of the Mediterranean Hospital of Cyprus, Dr. Andreas Panayiotou has set as a goal the development and the establishment of a reliable infirmary, with flexible operational mechanisms, in order to gain the trust and recognition for the quality of its services from everybody. Mediterranean Hospital of Cyprus is the first private hospital that joined Cyprus’ General HealthCare System (GHS).

Website: www.medihospital.com.cy/en/

About I-DANTE LTD

Founded in December of 2019 by Etna Digital Growth (a consultancy- software house company in Italy) and CircleServus LTD (a consultancy company in Cyprus) in order to build digital healthcare solutions leveraging the power of the VeChainThor Blockchain.

Website: www.i-dante.com/

About VeChain

Launched in 2015, VeChain connects blockchain technology to the real world by providing a comprehensive governance structure, a robust economic model, and IoT integration. VeChain is the pioneer of real-world applications using public blockchain technology, with international operations in Singapore, Luxembourg, Tokyo, Shanghai, Paris, Hong Kong, and San Francisco. Together with our strategic partners PwC and DNV GL, we have established cooperative relations with many leading enterprises in different industries, including Walmart China, BMW, BYD Auto, Haier, H&M, LVMH, D.I.G, ENN, AWS, PICC, ASI etc.

Website: www.vechain.com 

Photo – https://techent.tv/wp-content/uploads/2020/05/vechain-and-i-dante-partnered-to-create-blockchain-enabled-medical-data-management-platform-for-healthcare-provider-in-cyprus.jpg

Logo – https://techent.tv/wp-content/uploads/2020/05/vechain-and-i-dante-partnered-to-create-blockchain-enabled-medical-data-management-platform-for-healthcare-provider-in-cyprus-1.jpg

PR Newswire

Leica Biosystems launches Aperio GT 450 DX in Asia enabling high volume clinical labs to scale up digital pathology operations

Leave a comment

VISTA, California, May 12, 2020 /PRNewswire/ — Leica Biosystems, the global leader in pathology workflow solutions, announced today that it has launched the Aperio GT 450 DX, its next generation digital pathology scanner, in the APAC region. With continuous loading, no-touch operation, and 32 second scan time at 40x magnification, the Aperio GT 450 DX, registered as CE IVD and TGA, allows healthcare organizations to scale up digital pathology so they can meet ever-increasing demands without sacrificing quality.

Leica Biosystems launches Aperio GT 450 DX in Asia enabling high volume clinical labs to scale up digital pathology operations
Leica Biosystems launches Aperio GT 450 DX in Asia enabling high volume clinical labs to scale up digital pathology operations

The Aperio GT 450 DX System was rigorously tested by technicians and pathologists in Asia, including at Seoul National University Hospital (SNUH), a leading digital pathology hospital in South Korea, to determine the workflow impact.

“The Aperio GT 450 DX next generation imaging solution innovatively reduces the pre-scan process and scanner technician time, while maintaining sharp image quality and color for the pathologist. We expect that these workflow time savings will allow us to scale up our digital pathology operations instead of using the current conventional glass slide-based diagnosis,” said Prof. Kyoungbun Lee, Department of Pathology, Seoul National University Hospital, who led the beta testing of the Aperio GT 450 DX.

“We are excited about this innovative product as it delivers the benefit of improved throughputs, reduced turnaround time and high-quality images for our healthcare professionals,” said Colin White, Global Vice President, Advanced Staining and Imaging at Leica Biosystems.

For In Vitro Diagnostic Use. The clinical use claims described for the products in the information supplied have not been cleared or approved by the U.S. FDA or are not available in the US.

Aperio GT 450 at Leica Biosystems Virtual Digital Pathology Summit
On May 19th and 20th, 2020, thought leaders from around the globe will gather to showcase talks on the latest topics and advances in digital pathology whilst providing a collaborative and interactive experience in a virtual environment. Learn more about the Aperio GT450 DX during this virtual summit.

About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps.  Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture.  Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.

Media Contact: Melissa Crothers, Global Marketing Communications Manager
Phone: 760-539-1193
Email: LBS-GlobalMarketing@leicabiosystems.com 

Photo – https://techent.tv/wp-content/uploads/2020/05/leica-biosystems-launches-aperio-gt-450-dx-in-asia-enabling-high-volume-clinical-labs-to-scale-up-digital-pathology-operations.jpg

PR Newswire

Creality, a Global 3D Printer Manufacturer, Printed Medical Supplies for Hospitals Amid Supply Chain Challenge During COVID-19

Leave a comment

SHENZHEN, China, May 1, 2020 /PRNewswire/ — Creality, a global 3D printer manufacturer based in Shenzhen, China, was providing 3D printed medical supplies for hospitals. According to Jack Chen, the CEO and co-founder of the company, Creality was utilizing 100 3D printers and TPU filaments to produce 3D printed face mask buckles, achieving a daily output of 1600 pieces. By March, the company donated 43,000 pieces of buckles to hospitals.

“The COVID-19 has taught us a lesson that 3D printing is so helpful to strategically address manufacturing risk by optimizing the agility of the supply chain. It carries out production at a lower economic scale and any point of need. We are glad that 3D printing is unleashing great potential during this crisis, and Creality is taking the lead to contribute more,” said Jack Chen. Creality has achieved a monthly shipment of over 50,000 pieces in March, which means that more makers are getting involved in making PPE on 3D printers.

The COVID-19 is becoming such a challenge for countries across the world as the situation is getting more severe. During the time, 3D printing has played an important role in mitigating personal protective equipment (PPE) shortage. Enterprises and civil communities are united to make 3D printed medical supplies for hospitals and clinics.

The Supply Chain Challenge During COVID-19

The rapid development of globalization enables developed countries to relocate production into other countries with lower labor costs or sufficient raw materials, which is so-called offshore manufacturing. However, the present global crisis is exposing the vulnerabilities concerning this-type supply chain. The lockdowns have multiplied the problems of the slowdown in production and suspensions in transportation. Therefore, countries that highly rely on offshore manufacturing are facing problems of improper resource allocation and incomplete manufacturing chain, and countries in less developed areas such as Africa are encountering plight of insufficient production capacity and technology limit.

Many manufacturers are finding temporary alternative solutions to ride out this worldwide challenge. Thanks to the advanced technologies such as IoT, AI, robotics, and Additive manufacturing, enterprises can effectively avoid negative effects caused by “black swan” events like COVID-19.

3D Printing is Making a Difference

Recently, positive reports about 3D printed PPE to help combat COVID-19 have unveiled great advantages of 3D printing.

During the pandemic, researchers made 3D printed COVID-19 infected lung model to perform studies, enterprises made 3D printed isolation wards to accommodate patients, and civil communities made 3D printed face shields to mitigate the PPE shortage.

David Sims, the BBC news reported 3D printing enthusiast in Wales, UK, worked on making 3D printed face shields on Creality Ender-3 together with local volunteers to protect local NHS doctors fighting at the epidemic frontline. The team has donated thousand pieces of face shields to the local NHS.

It is proven that 3D printing is an extremely helpful stopgap in rapid design and manufacturing tools for both organizations and individuals, making it possible to produce large batches of equipment in a short period. During the COVID-19, 3D printing has unleashed great power in providing self-made daily supplies such as door handles, toys, or gifts.

Long-run Benefits of 3D Printing

Expect for the known-to-all advantages like cost-saving, time-saving, rapid-prototyping, 3D printing also accelerates digitalizing the traditional mass manufacturing and infrastructure construction. 3D printing breaks the limits of time and space to improve production capacity and reduce risks to fluctuations in demand. With the advantages of distributive manufacturing, 3D printing can realize customizable production and ensure production safety at the same time. As an additive in mass manufacturing, it will greatly improve business flexibility, allowing manufacturers to increase their ability to quickly respond to the possible crises. 

In April, Creality announced to make a big investment to Wuhan to build the world’s largest 3D printer production facility in recent years, aiming to achieve a total output of 2 million pieces of 3D printers within the next three years. Now the company is holding a Kickstarter campaign for its latest product CR-6 SE featuring an innovative leveling-free tech, which will be priced lower than 300$ at its super early bird price. Bearing the spirit of 3D printing industry evangelist, Creality has always devoted to spreading the convenience of 3D printing technology with the most affordable and accessible 3D printing solutions.

About Creality

Creality has accumulated more than 5 years of experience in 3D printing industry since its establishment in 2014. The company dedicates to providing customers the most affordable 3D printing solutions in high quality. Creality achieves an annual shipment of 800,000 units, and exports the products to over 100 countries.

For more information, please access to CRAELITY official website: http://www.creality.com

Cision View original content:http://www.prnewswire.com/news-releases/creality-a-global-3d-printer-manufacturer-printed-medical-supplies-for-hospitals-amid-supply-chain-challenge-during-covid-19-301049433.html

PR Newswire

Berkeley Lights Launches Two New Capabilities in the Opto Cell Therapy Development 1.0 Workflow to Accelerate the Creation Of Effective Cancer Immunotherapies

Leave a comment

The new multiplex cytokine and cytotoxicity assays as a part of the Opto Cell Therapy Development 1.0 workflow will help users of the Berkeley Lights’ platform develop cancer immunotherapies faster

EMERYVILLE, Calif., April 28, 2020 /PRNewswire/ — Today, Berkeley Lights, Inc., a leader in Digital Cell Biology, launched new capabilities to empower the Opto Cell Therapy Development 1.0 workflow. The workflow consists of a collection of software capabilities, reagents, and protocols to be run on the Beacon® and LightningTM systems. With the new capabilities researchers can now perform multiple functional assays on thousands of individual T cells in just days, allowing them to recover live cells for downstream genomic analysis. This ultimately enables Berkeley Lights’ customers to link T cell phenotype and function to genotype on individual cells, consolidating the T cell functional analytic process into one innovative platform.

T cell-based therapies have shown great promise for cancer treatment, but developing these therapies is challenging because the process of killing cancerous tumors by T cells relies on studying and screening multiple cell-to-cell interactions—a time-consuming and complex procedure. Current techniques to assess T cell function don’t allow scientists to collect all of the required data from the same cell. The new multiplex cytokine assay and the cytotoxicity assay, along with the recently launched TCRseq Well Plate Kit allow scientists to define and test the function of individual T cells. These applications enable simultaneous functional interrogation of thousands of individual T cells as they interact with antigen-presenting cells or tumors. Live, individual clones can be recovered for downstream expansion or genomic analysis. The Opto Cell Therapy Development 1.0 workflow enables CAR-T cell phenotypic and functional screening, and the discovery of T cell receptors (TCRs) associated with specific T cell behaviors.

“With the Opto Cell Therapy Development 1.0 workflow, users of Berkeley Lights’ platform can now tailor the development of cell therapies that mediate the rapid destruction of multiple tumor cells to the few T cells that really do all the work,” said John Proctor, Ph.D., Senior Vice President of Marketing at Berkeley Lights. “The cytotoxicity assay visualizes killing activity from single T cells, such as multiplexed and serial killing, followed by live cell recovery for genomic analysis. This new assay avoids common problems associated with traditional killing assays, which measure average target cell lysis at fixed time points, obscuring kinetic details and ignoring the heterogeneity present in T cell subsets.”

Berkeley Lights will continue to release more cell therapy related capabilities to the Berkeley Lights platform in the coming months. Email info@berkeleylights.com for more info.

About Berkeley Lights
 Here at Berkeley Lights, we think cells are awesome! Cells are capable of manufacturing cures for diseases, fibers for clothing, energy in the form of biofuels, and food proteins for nutrition. So the question is, if nature is capable of manufacturing the products we need in a scalable way, why aren’t we doing more of this? Well, the answer is that with the solutions available today, it is hard. It takes a long time to find the right cell for a specific job, costs lots of money, and if you have picked a suboptimal cell line, has a very low process yield. The Berkeley Lights Platform delivers and links deep phenotypic, functional, and genotypic information at the single cell level. This is a new way to capture and interpret the qualitative language of biology and translate it into single cell specific digital information, which we call Digital Cell Biology. Using our platform, customers have the complete solution to find the best cells by functionally screening and recovering individual cells for antibody discovery, cell line development, cell therapy development, and synthetic biology. Using our systems and solutions, scientists can find the best cells, the first time they look. For more information, visit www.berkeleylights.com.

Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are for research use only. Not for use in diagnostic procedures.

Logo – https://techent.tv/wp-content/uploads/2020/04/berkeley-lights-launches-two-new-capabilities-in-the-opto-cell-therapy-development-1-0-workflow-to-accelerate-the-creation-of-effective-cancer-immunotherapies.jpg  

Source: Berkeley Lights, Inc.